Auris Medical : Corporate Presentation June 2021

Company Presentation

2021 LD Micro Invitational XI - June 9, 2021

Forward-looking Statements

This presentation may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical facts and may include statements that address future operating, financial or business performance or Auris Medical's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may", "might", "will", "should", "expects", "plans", "anticipates", "believes", "estimates", "predicts", "projects", "potential", "outlook" or "continue", or the negative of these terms or other comparable terminology. Forward- looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to,

the approval and timing of commercialization of AM-301, Auris Medical's need for and ability to raise substantial additional funding to continue the development of its product candidates, the timing and conduct of clinical trials of Auris Medical's product candidates, the clinical utility of Auris Medical's product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical's intellectual property position and Auris Medical's financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical's capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Auris Medical's Annual Report on Form 20-F for the year ended December 31, 2020, and in Auris Medical's other filings with the SEC, which are available free of charge on the Securities Exchange Commission's website at: www.sec.gov. Should one or more of these risks or

uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated. All forward-looking statements and all subsequent written and oral forward- looking statements attributable to Auris Medical or to persons acting on behalf of Auris Medical are expressly qualified in their entirety by reference to these risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law.

2

Auris Medical at a glance

• A biomedical company in full transformation
• Headquartered in Bermuda / operations in Switzerland

RNA therapeutics

Extrahepatic targets

Preclinical

Allergy and viral infection

OTC nasal spray (BentrioTM)

Pre-launch

Vertigo	Tinnitus and hearing loss
Rx nasal spray	Rx intratympanic
Phase 2	Phase 3 → partnering

EARS → CYTO

New focus

Spin-off or divestiture 12-18 mos

3

RNA Therapeutics

4

Acquisition

of Trasir

Therapeutics,

Inc.

Privately held, based in Tampa FL

Pioneer in extrahepatic nucleic acid delivery

OligoPhoreTM platform

World-wide exclusive license from Washington University

Share-based transaction

Transaction closed on June 1, 2021

5